Rivastigmine: Uses, Dosage, Side Effects & More

When working with Rivastigmine, a reversible cholinesterase inhibitor prescribed for mild‑to‑moderate Alzheimer’s disease and Parkinson’s disease dementia. Also known as Exelon, it works by increasing acetylcholine levels in the brain, which can slow cognitive decline.

Alzheimer’s disease is a progressive neuro‑degenerative disorder marked by memory loss and impaired thinking. Parkinson’s disease dementia shares similar cholinergic deficits, making Rivastigmine a useful option for both conditions. As a cholinesterase inhibitor, it blocks the breakdown of acetylcholine, supporting neuronal communication and helping patients maintain daily function. Dosage starts low—typically 1.5 mg twice daily for oral capsules—and may be titrated to 6 mg twice daily based on tolerance and therapeutic response. For patients with renal impairment, dose reduction is recommended to avoid accumulation and side effects such as nausea, weight loss, or tremor.

When prescribing Rivastigmine, clinicians monitor cognitive scores, gastrointestinal tolerance, and cardiac status, because the drug can influence heart rate in sensitive individuals. Real‑world experience shows that transdermal patches can improve adherence for those who struggle with oral dosing, delivering a steady 4.6 mg/24 h release over a week. Expecting side effects? Most are mild and fade after a few weeks, but persistent vomiting or severe dizziness warrants a dose adjustment or switch to an alternative agent. Below you’ll find a curated set of articles covering dosage strategies, safety considerations, and comparative reviews of other dementia therapies—giving you a clear roadmap to manage patients effectively.